Keyphrases
Indonesia
100%
Surabaya
74%
Lopinavir
49%
Drug Combination
49%
In Vitro Study
49%
Hydroxychloroquine
49%
Azithromycin
43%
SARS-CoV-2 Virus
39%
COVID-19
38%
Tuberculosis Patients
34%
Natural Killer Cells
34%
Doxycycline
34%
Multidrug-resistant Tuberculosis (MDR-TB)
28%
Dual Drug
27%
Randomized Double-blind
24%
Viral Inactivation
24%
Pulmonology
24%
Critically Ill COVID-19 Patients
24%
B Vitamin Supplementation
24%
Clinical Impact
24%
Moderate COVID-19
24%
Multicenter Clinical Trial
24%
Adverse Drug Reaction
24%
Intensive Phase
24%
Referral Hospital
24%
Hospitalized Patients
24%
Shorter Regimen
24%
Rifampicin-resistant Tuberculosis
24%
Tuberculosis Treatment
24%
COVID-19 Infection
24%
Interleukin-12 (IL-12)
24%
Multidrug Resistance
24%
Antiviral Agents
24%
Antibiotics
24%
Multidrug-resistant
24%
Bacterial Infection
24%
Hematopoietic Stem Cells
24%
Vitamin B1
19%
Adverse Effects
14%
COVID-19 Patients
13%
Viral Load
13%
COVID-19 Cases
12%
B12 Supplementation
9%
Intervention Group
9%
Tuberculosis
9%
Cell-based
9%
Vitamin B6
9%
Favipiravir
9%
TB Patients
9%
Vero Cells
8%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
54%
SARS Coronavirus
49%
Lopinavir Plus Ritonavir
49%
Combination Drug
49%
Hydroxychloroquine
49%
Azithromycin
43%
Multi-Drug-Resistant Tuberculosis
37%
Doxycycline
34%
Extensively Drug-Resistant Tuberculosis
24%
Vitamin B Group
24%
Side Effect
24%
Adverse Drug Reaction
24%
Rifampicin
24%
Mixed Infection
24%
Interleukin 12
24%
Antivirus Agent
24%
Retrospective Study
24%
Quinolone Derivative
24%
Drug Resistant Tuberculosis
24%
Bacterial Infection
24%
Clinical Study
24%
Antibiotics
24%
Multidrug Resistance
24%
Vitamin B12
19%
Thiamine
19%
Prevalence
10%
Pyridoxine
9%
Favipiravir
9%
Cytotoxicity
9%
Tumor Necrosis Factor
7%
Interleukin 10
7%
Interleukin 6
7%
Treatment Group
6%
Pharmacotherapy
6%
Combination Therapy
6%
Clarithromycin
6%
IC50
6%
Diseases
6%